Acetylsalicylic acid, the active ingredient in Polocard, when given in small doses inhibits platelet aggregation (clumping). This makes it important in preventing blood clots. Dosage This medicine should always be taken as described in the patient information leaflet or as directed by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist. Take this medicine by mouth, preferably with or after a meal, with a small amount of water. Use the lowest effective dose possible to reduce the risk of side effects. Dosage 1 - 2 75 mg tablets or 1 150 mg tablet per day.
In fresh myocardial infarction or in patients with suspected fresh myocardial infarction, the initial saturating dose is: 225 mg (3 tablets of 75 mg) to 300 mg (2 tablets of 150 mg or 4 tablets of 75 mg) of acetylsalicylic acid once daily to achieve rapid inhibition of platelet aggregation. Tablets should be chewed to achieve rapid absorption. Indications Prophylaxis of cardiovascular diseases that are at risk for thrombosis and embolism in blood vessels myocardial infarction, unstable and stable ischemic heart disease prophylaxis of other diseases that involve clots in vessels. Substance The active ingredient is acetylsalicylic acid.
1 tablet contains 75 mg or 150 mg of acetylsalicylic acid. The other ingredients are: corn starch, cellulose powder, sodium carboxymethyl starch, hypromellose, methacrylic acid copolymer, triethyl citrate, titanium dioxide (E171), talc, sodium lauryl sulfate, cochineal red, lac (E 124), colloidal silica anhydrous, sodium bicarbonate. Contraindications Do not use Polocard if you are allergic to acetylsalicylic acid or any of the other ingredients if you are allergic to other NSAIDs with symptoms such as bronchospasm, hay fever, or shock. if you have severe hepatic, renal, or cardiac insufficiency If the patient has severe hepatic, renal or cardiac insufficiency if the patient has a blood clotting disorder and is receiving concomitant treatment with anticoagulants (coumarin derivatives, heparin), if the patient has glucose-6-phosphate dehydrogenase deficiency if the patient is concomitantly receiving methotrexate at doses of 15mg per week or more because of its deleterious effect on bone marrow. in children under 12 years of age, especially in the setting of viral infections, because of the risk of Reye's syndrome, a rare but severe disease causing liver and brain damage during the last trimester of pregnancy. The drug is contraindicated in children and adolescents under 16 years of age.
.
